Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06243172
Other study ID # H-22014311
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 1, 2024
Est. completion date May 1, 2025

Study information

Verified date January 2024
Source Steno Diabetes Center Copenhagen
Contact Helena Z Wodschow, MD
Phone +45 30313426
Email helena.zander.wodschow.03@regionh.dk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of the present clinical descriptive study is to characterize and quantify the potential hormonal chronobiological differences between individuals with type 2 diabetes (T2D) and healthy age and weight-matched controls as either circadian aligned or misaligned. The investigators hypothesize that individuals with T2D have a misaligned and different circadian rhythmicity of circadian biomarkers (melatonin and cortisol) than controls, and that this difference in turn is related to 24h hormonal fluctuations, behaviour, and metabolic-, cardiac-, and cognitive parameters. Participants will be asked to: - fill-out a diary on eating and sleeping habits for 30 days - wear an actigraphy and continuous glucose monitor for 10-14 days - stay overnight at the research facility, including continuous blood sampling and polysomnography


Description:

T2D is associated with cognitive dysfunction and an increased risk of developing dementia. This negative effect on cognition is worsened by T2D duration, yet the mechanisms are unknown. Sleep disturbances increase peripheral insulin resistance, and is associated with the development of T2D, temporarily worsened cognitive function, and the development of cognitive impairment. In turn, T2D is associated with circadian misalignment (a condition where the internal physiological clock is unaligned with the external behavior). A major external signal (also known as zeitgeber) for synchronizing the internal and external clock is sleep in accordance with the day-night cycle. Determining the circadian rhythm of an individual and whether it is aligned or misaligned is complex and can't be done by one measurement. However, melatonin and cortisol are often used as "circadian biomarkers" due to significant and well-defined circadian rhythm profiles. Another measure of the circadian phase is the timing of melatonin production under dim light conditions (dim light melatonin onset) which is an individual phase marker depending on the persons habitual time of sleep. Most studies focusing on circadian alignment in an everyday setting have used questionnaires, and to our knowledge, no studies have described 24-h circadian oscillations between individuals with T2D and healthy age and weight matched controls. Mapping these potential differences could help explain the pathophysiological mechanisms behind T2D and circadian misalignment. The Cir-D-Brain study is a clinical descriptive study. The study comprises of an information visit, a screening visit, a midway visit (2 weeks after screening), a 24-h in-hospital day (a day between the midway visit and the final visit), and a final visit (2 weeks after the midway visit). Participants will keep a diary on eating and sleeping habits for all 30 days. At the midway visit, participants will be equipped with an actigraphy and a continuous glucose monitor. At the 24-h in-hospital day, participants will have their blood sampled every third hour for 24 hours to measure their circadian rhythm, every hour from 6 pm till 12 am to map dim light melatonin onset, and at wake-up to map cortisol awakening response. At the 24-h in-hospital day, participants will furthermore have their sleep stages measured by polysomnography. The study will include 30 participants with T2D and 30 age and BMI matched controls. The specific objectives are: 1. To characterize and quantify the hormonal chronobiological differences between individuals with T2D and healthy matched controls measured by circadian biomarkers. 2. To relate the findings to 24-h hormonal fluctuations, different patterns in metabolism, behavioural circadian rhythms differences (sleep-wake and eating habits), sleep stages, glycaemic variability, inflammation, heart rate variability, and cognition.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date May 1, 2025
Est. primary completion date May 1, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 75 Years
Eligibility Inclusion Criteria: Individuals with T2D: - Informed and written consent. - Clinically diagnosed diabetes mellitus type 2 for at least 3 months (diagnosed according to criteria of World Health Organization (WHO)). - HbA1c >53 mmol/mol - Stable medical treatment for at least 8 weeks. - Plasma haemoglobin =8.00 mmol/L (male) or =6.4 mmol/L (female). - Male or female participants aged 50-75 years. Healthy matched controls: - Informed and written consent. - Normal haemoglobin =8.00 mmol/L (male) or =6.4 mmol/L (female). - Male or female participants aged 50-75 years. Exclusion Criteria: - Body mass index (BMI) <23 kg/m2 - Receipt of any investigational medicinal product within 3 months before screening in this trial. - Inability to perform neuropsychological tests (e.g., visual impairment or auditory impairment, or language barrier). - Participants with mental incapacity or language barriers precluding adequate understanding or co-operation or who, in the opinion of the investigator or their general practitioner, should not participate in the trial. - Prior or contemporary use of any kind of hypnotica within 6 months, former p.n. use of melatonin is judged by the investigator. - Nightshift-worker. - Known dementia or any other major disorders that in the opinion of the investigator precludes compliance with the protocol, evaluation of the results or represent an unacceptable risk for the participant's safety. - Diagnosed sleep disorders (e.g., sleep apnoea and narcolepsy). - Significant history of alcoholism or drug/chemical abuse as per investigator's judgement. - Severe hypoglycaemic event during the past 6 months requiring medical assistance. - Diagnosed diabetic retinopathy. - Severe renal insufficiency defined as estimated glomerular filtration rate (eGFR) = 30 ml/min/1.73m2 or any kind of kidney disease that in the opinion of the investigator involves an unnecessary risk for the participants. - Cardiac problems including any of the following: 1. Classified as being in New York Heart Association (NYHA) class III or IV. 2. Angina pectoris (chest pain) within the last 6 months. - Inadequately treated blood pressure at screening defined as repeated resting blood pressure outside the rage 90-150 mmHg for systolic and 50-100 mmHg for diastolic blood pressure. - Known lung disease that in the opinion of the investigator represents an unacceptable risk for the participant's safety. - Active or recent (= 12 months) malignant disease is judged by the investigator. - For females only: Pregnancy, breast-feeding status, or intention of becoming pregnant during the trial. - For healthy matched controls: prediabetes defined as HbA1c between 42-47 mmol/mol

Study Design


Locations

Country Name City State
Denmark Steno Diabetes Center Copenhagen Herlev

Sponsors (3)

Lead Sponsor Collaborator
Steno Diabetes Center Copenhagen Glostrup University Hospital, Copenhagen, University Hospital Bispebjerg and Frederiksberg

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Chronotype (diurnal preference) Morningness-Eveningness Questionnaire (scoring) At screening
Other Sleep apnea Apnea-hypopnea index (events/hour) 24-hour in-hospital day
Other Blood pressure variations Measured continuously by the polysomnograph (mmHg) 24-hour in-hospital day
Other Cardiovascular autonomic neuropathy Assessed from three standard cardiovascular autonomic reflex tests: lying-to-standing test, deep breathing test, and Valsalva manoeuvre At screening
Primary Melatonin oscillations (amplitude, peak, mesor, phase, period length (TAU)) Blood samples 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)
Primary Cortisol oscillations (amplitude, peak, mesor, phase, period length (TAU)) Blood samples 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)
Secondary Dim light melatonin onset Blood samples (pg/ml) 24-hour in-hospital day, blood samples taken every hour from 18:00 until 00:00 (7 timepoints in total)
Secondary Phase angle (time between dim light melatonin onset and sleep) Blood samples 24-hour in-hospital day, blood samples taken every hour from 18:00 until 00:00 (7 timepoints in total)
Secondary Cortisol awakening response Blood samples (pg/ml) 24-hour in-hospital day, blood samples taken at wake up, and 15-, 30-, and 60-minutes post-wake up
Secondary Diary on sleeping habits Expanded Consensus Sleep Diary (time in bed, time to fall asleep, number of awakenings and durations, time of final awakening, time to get out of bed, total sleep time, sleep quality, daytime sleepiness, number of naps and duration, number and last time of alcohol consumption, number and last time of coffein consumption, use of sleep medicine) 30 days
Secondary Diary on eating window The eating window (initiation of first consumption and termination of last consumption of food) 30 days
Secondary Glycaemic variability Continuous glucose monitor (amplitude (mmol/L), frequency, and duration of the fluctuation, mean glucose (mmol/L), time in range, time in hyperglycemic and hypoglycemic range, area under the curve) 10-14 days
Secondary Sleep and waking states Actrigraph worn on the wrist of the non-dominant hand (acceleration at different times) 10-14 days
Secondary Heart rate variability (fluctuations in time intervals between adjacent heart beats) Measured continuously by the polysomnograph (ms) 24-hour in-hospital day
Secondary Sleep architecture Polysomnography (minutes and percentages). Sleep stages (N1, N2, N3, rapid eye movement (REM)), total time asleep, sleep latency, REM sleep latency, arousals, awakenings, total sleep efficiency. 24-hour in-hospital day
Secondary Cognition (verbal memory) Rey Auditory Verbal Learning Test (RAVLT) 24-hour in-hospital day
Secondary Cognition (psychomotor speed and executive function) Trail Making Test (TMT) part A and B ), Symbol Digit Modalities Test (SDMT) 24-hour in-hospital day
Secondary Cognition (executive function) WAIS-III Letter-Number Sequencing test, Verbal fluency test (letters S and D) 24-hour in-hospital day
Secondary Cognition (sustained attention) Rapid Visual Processing (RVP) test from the Cambridge Neuropsychological Test Automated Battery (CANTAB) 24-hour in-hospital day
Secondary Cognition (verbal IQ) Danish Adult Reading Test (DART) (equivalent to the National Adult Reading Test; NART) 24-hour in-hospital day
Secondary Insulin oscillations (amplitude, peak, mesor, phase, period length (TAU)) Blood samples. 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)
Secondary C-peptide oscillations (amplitude, peak, mesor, phase, period length (TAU)) Blood samples. 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)
Secondary TSH oscillations (amplitude, peak, mesor, phase, period length (TAU)) Blood samples. 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)
Secondary Glucose oscillations (amplitude, peak, mesor, phase, period length (TAU)) Blood samples. 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)
Secondary Glucagon oscillations (amplitude, peak, mesor, phase, period length (TAU)) Blood samples. 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)
Secondary Glucagon-like peptide-1 (GLP-1) oscillations (amplitude, peak, mesor, phase, period length (TAU)) Blood samples. 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A